TICKERNERD
Menu
ANNXANNXHealthcare · Biotechnology

ANNX Stock Forecast: Annexon, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$4.00
−0.25% on the day

The 10 Wall Street analysts covering Annexon, Inc. hold a median 12-month price target of $14 — +250.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$760.2M
Ticker Nerd rank
38 / 100
Median analyst target
$14
Analysts covering
10
Revenue$0.0
Operating income−$57.2M
Net income−$55.3M
Free cash flow−$48.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.9%
1M
−14.3%
YTD
−20.3%
1Y
+27.0%
From 52W high
−42.5%
From 52W low
+49.3%
$2.68
$6.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Annexon, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
69
Accruals
64
Volatility
63
Growth
62
Size
48
Value
46
Issuance
42
Revisions
28
Quality
21

Momentum (69): The shares have been drifting up relative to others.

Quality (21): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00Jan 26Apr 26Jul 26Oct 26ANNXHigh $27Median $14Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $7Median $14High $27

The green dot is the last close — the median target sits +250.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 Sept 2026JP MorganMaintainsOverweight$14 → $15
1 Sept 2026JP MorganMaintainsOverweight—
1 Sept 2026JP MorganMaintainsOverweight$10 → $14
13 Aug 2026CitizensUpgradeMarket Perform—
13 Aug 2026CitizensUpgradeMarket Perform—
21 July 2026CitizensInitiatesMarket Underperform$3.00
21 July 2026CitizensInitiatesMarket Underperform—
15 July 2026NeedhamMaintainsBuy$11 → $25
15 July 2026NeedhamMaintainsBuy—
12 May 2026Goldman SachsInitiatesNeutral—
20 Mar 2026Chardan CapitalMaintainsBuy—
23 Dec 2025Chardan CapitalInitiatesBuy—
2 Dec 2025Clear StreetInitiatesBuy—
19 Nov 2025Wells FargoMaintainsOverweight—
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
14 May 2025HC Wainwright & Co.MaintainsBuy—
13 May 2025NeedhamMaintainsBuy—
4 Mar 2025NeedhamReiteratesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Annexon, Inc. returned +27.0% against +16.2% for the S&P 500, dividends included.

ANNX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Jan 26Apr 26Jul 26Oct 26ANNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
5
Fundamentals

Annexon, Inc. (ANNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.0×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
3.8×

Cheaper than 26% of US stocks

EV / EBITDA
−2.8×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−105.3%

Higher than 13% of US stocks

Return on assets
−51.5%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Annexon, Inc. (ANNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Annexon, Inc. has a market value of $760.2M and an enterprise value of $579.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$202.7M.

  • Diluted earnings per share, trailing twelve months: $−1.16.

  • Free cash flow in the twelve months to 30 June 2026: −$193.2M.

  • Shares outstanding: 174.6M.

  • Trailing P/E: −3.0×; forward P/E: −3.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Annexon, Inc. employs 92 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ANNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANNXAnnexon, Inc.$760.2M
38
APMDApnimed, Inc.$758.4M
1
OBXObsidian Therapeutics, Inc.$755.5M
59
GYREGyre Therapeutics, Inc.$753.7M
45
IMMXImmix Biopharma, Inc.$770.2M
33
ATTOAttovia Therapeutics, Inc.$743.4M
0
ACHVAchieve Life Sciences, Inc.$738.1M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Annexon, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANNX news & analysis

Annexon: Preserving Patient Function Is The Real Investment Opportunity

Seeking Alpha · 27 Sept 2026neutral

Annexon is focusing on functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation through preservation of vision and physical recovery. The company maintains a cash runway into 2028 supported by $209.2M in liquidity and a $200M Oxford Finance facility, with ARCHER II trial readouts expected in Q4 2026.

Why it matters — A watcher would care because the ARCHER II trial's shift to functional vision endpoints and the 2026 readouts could determine whether Annexon achieves clinical differentiation and market expansion in geographic atrophy.

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

GlobeNewsWire · 24 Sept 2026positive

Annexon announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting, covering patient baseline characteristics from the Phase 3 ARCHER II pivotal trial for geographic atrophy as well as Phase 2 vision protection data. The company noted month 15 results from ARChER II are expected in the fourth quarter of 2026.

Why it matters — A watcher of ANNX would care because these presentations highlight the positioning of the Phase 3 ARCHER II trial to potentially replicate Phase 2 vision outcomes, providing insight into the program's progress ahead of the anticipated 2026 readout.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 16 Sept 2026neutral

Annexon announced that it granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on September 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This news is relevant to Annexon watchers as it reflects the company's hiring and equity compensation activity, though it does not directly affect its pipeline or financial results.

Annexon to Participate in Upcoming September Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Annexon, Inc. announced that its president and chief executive officer, Douglas Love, Esq., will participate in fireside chats at several investor conferences during September. The company is a biopharmaceutical firm developing targeted immunotherapies for neuroinflammatory diseases.

Why it matters — Annexon watchers would care because the CEO's participation in September investor conferences offers opportunities for the company to present its platform and engage with the investment community.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 17 Aug 2026neutral

Annexon, Inc. announced that it granted inducement equity awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. The awards were approved on August 10, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This discloses new equity compensation for incoming employees, a routine corporate action that ANNX watchers may note for governance and hiring activity.

FAQ

Frequently asked questions about ANNX stock

What is the ANNX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Annexon, Inc. have a median 12-month price target of $14, with estimates ranging from $7 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANNX stock a buy right now?

Of the 10 analysts covering Annexon, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Annexon, Inc. 38 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANNX?

As at 8 Oct 2026, Annexon, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (69 of 100).

Will ANNX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +250.0% from the last close, and Ticker Nerd's factor model ranks Annexon, Inc. 38 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANNX stock forecast for 2030?

No analyst covering Annexon, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $27 over the next 12 months.

How has ANNX stock performed over the past year?

Annexon, Inc. returned +27.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Annexon, Inc. do?

Annexon Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target classical complement-driven inflammation in diseases of the body, brain, and eye.

What is the latest news on ANNX?

The most recent item we track (Seeking Alpha, 27 Sept 2026): "Annexon: Preserving Patient Function Is The Real Investment Opportunity". Annexon is focusing on functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation through preservation of vision and physical recovery. The company maintains a cash runway into 2028 supported by $209.2M in liquidity and a $200M Oxford Finance facility, with ARCHER II trial readouts expected in Q4 2026.

Company

About Annexon, Inc.

Annexon Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target classical complement-driven inflammation in diseases of the body, brain, and eye. The company’s current pipeline includes investigational medicines for autoimmune, neurodegenerative, neuroimmune, and ophthalmic conditions, with programs designed to block C1q, the initiating molecule of the classical complement pathway. Its product candidates are being studied across areas such as Guillain-Barré syndrome, geographic atrophy, and other serious inflammatory disorders. Annexon’s work centers on complement biology, a mechanism involved in immune activation and tissue damage, giving the company a distinct position within precision immunotherapy research. Headquartered in Brisbane, California, Annexon serves the biotechnology and drug development market through clinical research, translational science, and late-stage therapeutic development.

CEO Mr. Douglas E. Love Esq., J.D. · 92 employees · United States · https://www.annexonbio.com